Cross Timbers Royalty Trust  

(Public, NYSE:CRT)   Watch this stock  
Find more results for CRT
30.28
-0.02 (-0.07%)
May 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 29.88 - 30.39
52 week 23.60 - 39.97
Open 29.92
Vol / Avg. 11,280.00/17,310.00
Mkt cap 181.68M
P/E 12.20
Div/yield 0.18/6.97
EPS 2.48
Shares 6.00M
Beta 0.69
Inst. own 13%
Feb 25, 2013
Q4 2012 Cross Timbers Royalty Trust Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 97.91% 97.42%
Operating margin 97.91% 97.42%
EBITD margin - 97.42%
Return on average assets 103.74% 104.60%
Return on average equity 112.58% 114.76%
Carbon Disclosure Rating - -

Address

17th Floor, 901 Main Street, P.O. Box 830650
DALLAS, TX 75283-0650
United States - Map
+1-877-2285084 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Cross Timbers Royalty Trust is an express trust. The net profits interests are the principal asset of the trust. The net profits interests consists of: the 90% net profits interests, which are carved from producing royalty and overriding royalty interest properties in Texas, Oklahoma and New Mexico, and 11.11% nonparticipating royalty interests in nonproducing properties located primarily in Texas and Oklahoma, and the 75% net profits interests, which are carved from working interests in four properties in Texas and three properties in Oklahoma. As of December 31, 2011, all underlying royalties, underlying nonproducing royalties and underlying working interest properties were owned by XTO Energy Inc. (XTO Energy). Approximately 20 of the underlying royalty interests in the San Juan Basin burden working interests in properties operated by XTO Energy. Bank of America, N.A. is the trustee of the trust.

Officers and directors

Louis G Baldwin Chief Financial Officer, Executive Vice President
Age: 62
Bio & Compensation  - Reuters
Nancy G. Willis Vice President
Bio & Compensation  - Reuters